



Genocea Biosciences
Investor Relations Department
100 Acom Park Drive, 5th Floor
Cambridge, MA 02140
United States

Visit IR website [↗](#)
Sign-up for Email alerts [↗](#)

NASDAQ: GNCA

Last Trade:	1.16
Trade Time:	4:00 PM ET Mar 16, 2018
Change:	0.00 (0.000%)
Day Range	1.13 - 1.21
52-Week Range	0.79 - 7.29
Volume	4,805,233

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Genocea aims to transform vaccine discovery and development to improve millions of lives. We use ATLAS™, our proprietary technology platform that rapidly identifies T cell antigens associated with protective immune responses in humans exposed to a pathogen. We have a pipeline of novel vaccine candidates that stimulate the T cell arm of the immune system, which is increasingly recognized as critical to generating protective immunity against a wide array of diseases. Genocea's pipeline includes clinical programs addressing genital herpes and pneumococcus and research efforts in... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Mar 12, 2018*
[Genocea Appoints Narinder Singh as SVP Pharmaceutical Sciences & Manufacturing](#)
- Mar 5, 2018*
[Genocea to Present at Two March Investor Conferences](#)
- Feb 15, 2018*
[Genocea Reports Fourth Quarter and Full-Year 2017 Financial Results](#)
- Feb 12, 2018*
[NEA Partner Ali Behbahani, M.D. Joins Genocea Biosciences' Board of Directors](#)
- Feb 8, 2018*
[Genocea to Host Fourth Quarter and Year End 2017 Financial Results Conference Call & Webcast on February 15, 2018 at 9 a.m. ET](#)

Financials [\[View all \]](#)

- [Fourth Quarter Financial Results](#)
- Feb 16, 2018*
[Annual Report \(10-K\)](#)
- Apr 21, 2017*
[Proxy Statement \(DEF 14A\)](#)
- Nov 3, 2017*
[Quarterly Report \(10-Q\)](#)
- Aug 9, 2017*
[Quarterly Report \(10-Q\)](#)
- May 5, 2017*
[Quarterly Report \(10-Q\)](#)